MENU

TCRX TScan Therapeutics Forecast, Technical & Fundamental Analysis

TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer... Show more

TCRX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
View a ticker or compare two or three
TCRX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

TCRX is expected to report earnings to fall 21.74% to -18 cents per share on November 11

TScan Therapeutics TCRX Stock Earnings Reports
Q3'26
Est.
$-0.18
Q2'26
Beat
by $0.03
Q1'26
Missed
by $0.04
Q4'25
Beat
by $0.09
Q3'25
Beat
by $0.06
The last earnings report on August 12 showed earnings per share of -23 cents, beating the estimate of -25 cents. With 200.23K shares outstanding, the current market capitalization sits at 14.65M.
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LARK32.971.96
+6.32%
Landmark Bancorp Inc.
ZS237.766.43
+2.78%
Zscaler
IQ0.90-0.01
-1.30%
iQIYI
PARR80.18-4.52
-5.34%
Par Pacific Holdings
ELOG1.04-0.08
-7.14%
Eastern International Ltd

TCRX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, TCRX has been loosely correlated with CELC. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if TCRX jumps, then CELC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TCRX
1D Price
Change %
TCRX100%
N/A
CELC - TCRX
36%
Loosely correlated
+2.60%
QURE - TCRX
35%
Loosely correlated
-0.11%
MGX - TCRX
33%
Loosely correlated
-0.30%
AGIO - TCRX
33%
Poorly correlated
+1.47%
MLTX - TCRX
32%
Poorly correlated
+3.20%
More
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
830 Winter Street
Phone
+1 857 399-9500
Employees
142
Web
https://www.tscan.com